Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PORT Q10: Reduced Coenzyme Q10 for Diarrhea During Radiotherapy in Gynecologic Cancer
jRCTs051210039Completed
- Sponsor
- Kaneka
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of coenzyme q10 in Cervical Cancer (CC), endometrial cancer (EC), vaginal cancer and 1 more (2 arms), sponsored by Kaneka. Primary endpoint: Maximum increase in defecation frequency per day during radiotherapy. Started Aug 2021; status: completed.
02
Drugs
coenzyme q10
03
Conditions
Cervical Cancer (CC)endometrial cancer (EC)vaginal cancerradiation enteritis
Beyond the preview
Go deeper on jRCTs051210039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051210039.